Abstract 1762P
Background
Dissemination of research results, including data from clinical trials, is one of the essential responsibilities of all scientists. Moreover, whole community of researchers, patients, and general public, should have access to research data at earliest possible moment. However, significant delay between completion of the study and publication of its results has been observed; thus, we aimed to analyze the time from database lockdown to publication and factors that might be associated with it.
Methods
We analyzed all original publications reporting any clinical data published in 2020 and 2021 in 2 leading oncological journal – Journal of Clinical Oncology (JCO) and Annals of Oncology (AoO). Information of cut-off (database lock) date, publication date, type of the study and its sponsor has been extracted. Descriptive statistics, t-test and chi-square tests were used for statistical analyses.
Results
Overall, 652 articles (482 from JCO, 170 from AoO) has been identified - 63% (411) reported results of clinical trials, 47% (193) of them reporting data from clinical trials. Only 52.3% (341) of trials reported the cut-off date. Reports from clinical trials reported cut-off date more often than other studies (65.5% vs 29.9%, p<0.001). Median time from data cut-off to publication (PT) was 15.4 months (range 1.2-130.8), with PT of 12-24 months and >24 months being 45.2% (154) and 22.6% (77), respectively. Reports of studies other than clinical trials had PT>24m more often than clinical trials (36.1% vs 19%; p=0.003). Commercially sponsored studies reported cut-off date more often than academic studies (79.2% vs 41.4%; p<0.001) but there was no difference in PT depending on type of sponsor (p=0.170).
Conclusions
Despite presence of reporting guidelines, significant proportion of scientific publications do not report exact date of data cut-off or last follow-up what make difficult to assess topicality and maturity of data. Moreover, nearly one-quarter of publications report results that are older than 2 years. Causes leading to such disproportion and publication of outdated results may lead on the authors’, editors’ or publishers’ side and need to be studied in more depth to ensure timely publication of relevant research data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Sobczuk: Financial Interests, Personal, Other, Travel grant: Novartis; Financial Interests, Personal, Other, Travel Grant: MSD, BMS; Financial Interests, Personal, Invited Speaker: Swixx BioPharma, BMS, Gilead; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Stocks/Shares: CelonPharma; Non-Financial Interests, Institutional, Product Samples: Immutep; Non-Financial Interests, Leadership Role, Board Member, Chair of Young Oncologists Section: Polish Society of Clinical Oncology. P. Rutkowski: Financial Interests, Personal, Invited Speaker, honoraria for lectures: MSD, BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Merck, Sanofi, Blueprint Medicines, Philogen; Financial Interests, Personal, Invited Speaker: Merck, Sanofi, Novartis, AstraZeneca; Financial Interests, Institutional, Research Grant, research grant for ISS: Pfizer; Financial Interests, Institutional, Funding, research grant for institution: BMS; Non-Financial Interests, Member of Board of Directors: Polish Society of Surgical Oncology; Non-Financial Interests, Member of Board of Directors, President: Polish Oncological Society. All other authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23